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Abstract
Background: A bone scan is a common method for monitoring bone metastases in patients with advanced prostate
cancer. The Bone Scan Index (BSI) measures the tumor burden on the skeleton, expressed as a percentage of the total
skeletal mass. Previous studies have shown that BSI is associated with survival of prostate cancer patients. The
objective in this study was to investigate to what extent regional BSI measurements, as obtained by an automated
method, can improve the survival analysis for advanced prostate cancer.
Methods: The automated method for analyzing bone scan images computed BSI values for twelve skeletal regions,
in a study population consisting of 1013 patients diagnosed with prostate cancer. In the survival analysis we used the
standard Cox proportional hazards model and a more advanced non-linear method based on artificial neural
networks. The concordance index (C-index) was used to measure the performance of the models.
Results: A Cox model with age and total BSI obtained a C-index of 70.4%. The best Cox model with regional
measurements from Costae, Pelvis, Scapula and the Spine, together with age, got a similar C-index (70.5%). The overall
best single skeletal localisation, as measured by the C-index, was Costae. The non-linear model performed equally well
as the Cox model, ruling out any significant non-linear interactions among the regional BSI measurements.
Conclusion: The present study showed that the localisation of bone metastases obtained from the bone scans in
prostate cancer patients does not improve the performance of the survival models compared to models using the
total BSI. However a ranking procedure indicated that some regions are more important than others.
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Background
Bone scintigraphy is a very common examination for
patients with prostate cancer to verify or exclude sus-
pected metastatic disease. For patients with bone metas-
tases the extent of the tumor burden is associated with
survival [1,2]. The Bone Scan Index (BSI) was developed
in order to quantify the amount of metastases in bone
scans [3]. BSImeasures the tumor burden in bone as a per-
centage of the total skeletal mass and has been shown to be
associated with survival of patients with prostate cancer
[4]. Automated BSI methods [5] have been developed to
further increase the objectivity and clinical use of bone
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scans for patients with prostate cancer. Recent work has
shown that the total BSI value and BSI change between
bone scans are prognostic indicators and can be used as
an imaging biomarker for prostate cancer patients [6-8].
Some authors, however, suggest that the localisation of
metastases in specific regions in bone is predictive of sur-
vival [9,10]. Riguad and colleges divided prostate cancer
patients in two groups; one including patients having bone
metastases in the axial skeleton and the other including
patients with appendicular bone metastases.
They showed that median survival time was 53 and
29 months in patients with axial and appendicular bone
metastases respectively, and that those with axial disease
had better survival time than those with appendicu-
lar bone metastases [9]. Furthermore, Hovsepian et al.
divided prostate cancer patients into four categories
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depending on the findings on radiographs. They reported
that 87% of the individuals in category VI, i.e. those
with >25% tumor involvement of the proximal femur died
of prostatic cancer, in contrast to patients in risk category
I with no involvement of the lung and pubisischium and
with <25% involvement of the proximal femur, of these
48% died a disease specific death [10].
We would therefore like to investigate whether specific
localisation of the bone metastases measured by the auto-
mated BSI method can predict survival in prostate cancer
patients. We used Cox proportional hazards in the sur-
vival modeling to investigate the effect of going from the
total BSI measurement to twelve regional ones. To allow
for possible non-linear interactions between regional BSI
measurements we also employed amore flexible modeling
approach based on artificial neural networks [11].
Methods
Study population
All patients with the diagnosis of prostate cancer, who
during the period January 2002 – December 2008 had un-
dergone a whole-body bone scan at the Sahlgrenska
University Hospital, Gothenburg, Sweden, were retro-
spectively considered for inclusion in the study. If sev-
eral bone scan studies had been performed for the same
patient, only the last one was used. Seventeen patients
with images of insufficient quality and 48 patients previ-
ously included in the development phase of the automated
quantification method [7] were excluded, leaving 1,013
patients in the study population. The study was approved
by the Research Ethics Committee at Gothenburg
University.
Data collection
Survival data, collected from the computerized medical
records, were updated until September 24, 2010. The
cause of death was not known. The mean follow-up time
was 2.3 years with a total of 32% censored cases. Themean
age was 77 years (SD 9.1).
The percentage of the skeleton affected by tumor mass
on a bone scan was measured by calculating the BSI. We
have recently presented an automated method [7], based
on the clinically validatedmethodology for manually com-
puting BSI as presented by a group at the Memorial
Sloan-Kettering Cancer Center inNewYork [3,12,13].The
automated method is trained to mimic an expert reader
in distinguishing hotspots due to metastases from those
caused by factors such as degenerative disease or frac-
tures. A general description of how the computer method
is developed and validated, including hot spot detection,
feature extraction and artificial neural networks, is pre-
sented by Sadik et al. [14].
A manual correction was required in less than 5% of
the patients to exclude hotspots clearly misclassified and
representing for example a very large urinary bladder,
a urinary catheter attached to a drainage bag or urine
contamination. No other manual steps were applied.
The method is implemented in the commercially avail-
able software package EXINI bone™ (EXINI Diagnostics
AB, Lund, Sweden). The automated method has been
described in detail elsewhere [7,14]. In summary, the
skeleton is segmented into twelve different anatomical
regions such as the skull, ribs, lumbar spine, and pelvis
(see Figure 1).
Thereafter, hotspots are detected and classified as a
metastatic lesion or not. The area of a metastatic hotspot
is calculated and this area is divided by the area of the
corresponding anatomical region and multiplied by a con-
stant representing the weight fraction of that skeletal
region of the total skeleton. This product gives an esti-
mate of the volumetric fraction of the skeleton occupied
by the metastatic hotspot. The BSI is the sum of all such
fractions.
The distribution of BSI measurements in each skeletal
region for our study population is presented in Figure 2.
Descriptive statistics for each region can be found in
Table 1.
Statistical methods
To evaluate the prognostic capability of the BSI data two
methods were used: Cox proportional hazards (COX) and
Artificial Neural Networks (ANNs). COX [15] is based
on the assumption of proportional hazards and is in its
standard form (as used here) restricted to linear relations
between covariates. The performance of eachmethod was
measured using the C-index [16].
To evaluate the prognostic capability of each regional
BSI value individually, a COX model was created for each
region and their corresponding C-index performances
were compared. A correlation test indicated that age did
not correlate with BSI and was therefore included in
each model. Finally, a model with the total BSI was also
included in the comparison.
While two regions might possess similar prognos-
tic qualities when taken individually, there is still the
question to what degree they overlap with or comple-
ment each other. This overlap can be investigated using
backward elimination: first a model is created with all
regional information, then the model is tested with each
region missing. The region which resulted in the small-
est drop in C-index is considered the least important
and is removed. If two regions overlap (in the prog-
nostic sense) however, the choice of region to remove
is in the worst case completely arbitrary. To verify that
the removal is not arbitrary, and that the removed
region does in fact possess worse prognostic capabil-
ity, we simultaneously performed a forward addition
procedure.
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Figure 1 The twelve different regions used by the automatic process to compute BSI values.
Forward addition means that initially, a model with
no regional information is created. It thus includes only
age. As regions are selected for removal in the back-
ward elimination procedure above, a newmodel is created
which includes this newly removed region, as well as any
previous information. In other words, while backward
elimination starts with complete regional information as
well as age and ends with only age, forward addition
starts with just age and ends with all regional informa-
tion together with age. If there is significant correlations
between regions, then the forward addition models will
quickly reach the performance of the backward elimina-
tion models.
A question related to correlation is the possibility of
non-linear interactions between the regional BSI values.
To investigate this possibility we turned to a model based
on artificial neural networks (ANN) introduced in [11].
ANN is a machine learning technique that offers strong
non-linear capabilities. In order to increase generalization










































Figure 2 The distribution of BSI values in the different regions presented as box plots.
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Table 1 The BSI-values for the different skeletal regions
Covariate Mean Median STD Zeros Unique
Age 77.02 78.00 9.13 0.00% 7.46%
BSI 2.23 0.56 3.18 0.00% 47.46%
C_Spine 0.03 0.00 0.09 77.16% 6.27%
Clavicle 0.02 0.00 0.05 72.99% 4.33%
Costae 0.30 0.00 0.56 52.09% 21.34%
Femur 0.11 0.00 0.28 69.25% 12.69%
Humerus 0.04 0.00 0.14 80.45% 7.91%
L_Spine 0.31 0.12 0.40 40.45% 20.15%
Pelvis 0.78 0.13 1.23 41.04% 32.39%
Sacrum 0.17 0.00 0.45 63.28% 14.18%
Scapula 0.10 0.00 0.17 58.21% 10.30%
Skull 0.10 0.00 0.33 68.81% 11.64%
Th_Spine 0.21 0.04 0.32 40.30% 16.72%
Sternum 0.04 0.00 0.07 60.90% 4.63%
Besides the mean, median and standard deviation, the table also lists the
fraction of zeros, patients with no metastases in that region, and the fraction of
unique values, which in some respect describes the granularity of the data
which can be relevant for machine learning.
ensemble) with 3 hidden neurons each. Each ANN in the
ensemble was trained to maximize the C-index on a sub-
set generated with bagging [17]. The flexibility offered by
ANNs are accompanied with the caveat that it can be dif-
ficult to understand the interactions between the variables
due to the black box nature of the ANN. Understanding
the interactions is however not required in order to prove
their existence.
Following the same procedure as for the COX models
we used backward elimination to investigate the signifi-
cance that the ANN ensemble attributes to the covariates.
A covariate that is part of a non-linear interaction will be
attributed greater significance by a non-linear model than
by a linear model. It is possible to indicate the existence
of non-linear interactions by comparing the significance
attributed to each variable by the ANN ensemble to the
performance of a model trained only on that variable. A
variable that is important in a non-linear fashion would
have greater significance than would seem motivated
based on the performance of the linear model trained
using only that variable.
For both COX and ANN models, we used 20x3 fold
cross validation unless stated otherwise and normalized
the covariates and survival time to have zero mean and
standard deviation equal to one.
Results
Correlations
The Pearson correlations between the regional BSI mea-
surements, together with age and survival time, are shown
in Figure 3. There were no correlations between age and
any of the regional BSI values (|ρ| ≤ 0.1). We found ten
significant (p < 0.05) correlations with |ρ| ≥ 0.7 among
the regional BSI values. Sacrum had the least correlation
(no correlations with p < 0.05 and smallest average |ρ|),
whereas Th_Spine had the largest correlation (5 signifi-
cant correlations with |ρ| ≥ 0.7). All correlations were
computed for subset of BSI values larger than zero.
Cox analysis
Cox models were constructed using age and each of
the twelve regional BSI measurements. Figure 4 shows
the validation C-index resulting from 3-fold cross vali-
dation repeated 20 times. The result for the total BSI
(sum of all regional BSI values) is shown as the right-
most bar in the plot and, in average, resulted in the largest
C-index (0.704).Models withmeasurements coming from
the Pelvis, Costae, Th_Spine, L_Spine and the Scapula
obtained the best performance in terms of the validation
C-index. In average a Cox model with age and regional
measurements from the Costae obtained similar perfor-
mance compared to a model with age and total BSI.
Multivariate Cox results are presented in Figure 5 in
terms of both backward elimination and forward selec-
tion. Very little was gained using a multivariate approach
instead of using the total BSI or a single regional (e.g
Costae) measurement together with age. The best aver-
age multivariate Cox model obtained an average C-index
of 0.705 and included the regional BSI measurements
Costae, Pelvis, Scapula, L_spine, Th_spine and age.
Non-linear interactions
The results for ANNmodels trained with a single regional
BSI measurement together with age are similar to those
obtained from the Coxmodel. A high correlation could be
observed between regions which result in a high C-index
and those regions which have high information count
(large medians and standard deviations).
Figure 6 shows the C-index performance of ANN
ensembles trained on individual regions together with
age along the x-axis. The y-axis displays the significance
attributed to the region through the use of backward
elimination on an ensemble of ANNs. Cross validation
was not used here (as a sole exception) but the process
was repeated 10 times. The error bars indicate one stan-
dard deviation from the mean. Variables that have good
prognostic capabilities individually will be plotted to the
right side, and to the left if they have poor prognostic
capabilities, whereas variables which the model deems
important are plotted towards the top, and vice versa.
Thus the interesting part of the plot is the right and top
halves.
The top right quadrant contains the variables which
are both important individually and ranked highly by
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Figure 3 Pearson’s correlation coefficients between all twelve BSI regions, age and survival time (Stid). A red color indicates anti-correlation,
while the size of the ellipsis indicates the strength of the correlation where−1 ≤ ρ ≤ 1 (zero indicates no linear correlation).
the model. This is where the best linear predictors are
expected to be placed. Covariateswhich correlate to a high
degree with these will likely end up in the bottom right
quadrant. The most interesting section however is the top
left quadrant, here covariates will be placed which display
non-linear correlations. They would naturally fair worse
individually (towards the left) than together (towards the
top). No covariates were placed in that quadrant however


















































Figure 4 Importance of the different BSI regions based on the validation performance of Cox models in 20x3-fold cross validation. Here
each Cox model used one regional BSI measurement and age, except for the rightmost model which used age and the sum of all BSI measurements.





















































Figure 5 Importance of the different BSI regions based on the validation performance of Coxmodels in 20x3-fold cross validation.
Pictured here is the change in performance as regional information is added/removed due to backward elimination. The blue line illustrates the
situation where models start out with access to all regional information, and at each step the indicated region is removed. Similarly, at each step the
column that was removed is added to the models in the green line. The lines follow the median validation performance while the colored area
indicates one standard deviation from the mean.
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Figure 6 Investigating possible non-linear correlations in ANN ensembles. The bottom axis shows the univariate (linear) validation
performance of the regions. The left axis shows the multivariate ranking of the regions given as the drop in C-index when removing the regions
individually from a model trained on all regions. Non-linear effects would be expected to show up in the upper left quadrant.




The present study demonstrates that the localisation of
bone metastases obtained from the bone scans in prostate
cancer patients does not add any further clinical infor-
mation beyond that of the total BSI value. Two different
computational models were tested to investigate the effect
of regional BSI measurements. The standard Cox propor-
tional hazards model and one based on artificial neural
networks optimizing directly on the C-index performance
measure [11]. The C-index was used in this study to
evaluate regional BSI values since it directly measures
the models’ ability to sort the patients according to sur-
vival time, which can be useful for subsequent risk group
definitions. While the COX model models the survival
curve with linear interactions between the covariates, the
ANN model only outputs a prognostic index that opti-
mizes the C-index, but allows for non-linear interactions
between the covariates. Any advantages using regional
BSI measurements, in terms of maximizing the C-index,
should be discoverable in at least one of these two
models.
Our results show that both COX and ANN models give
similar C-index performance for the multivariate analy-
sis indicating that, in our study population, no significant
non-linear effects could be found (see Figure 6). No com-
bination of regional BSI measurements gave significantly
better performance than using the total BSI. However, the
analysis provides a ranking of the twelve BSI localisations,
and we found that some regions were more important
than others. Specifically a COX model with only BSI
information from Costae, Pelvis, Scapula, L_spine and
Th_spine performed equally well as a COX model with
the total BSI. It should be noted that there is a correlation
between important regions and the amount of non-zero
BSI measurements.
Our results differ from what Rigaud and colleges
and Hovsepian and colleges have found [9,10]. Rigaud
et al. suggest that prostate cancer patients suffering
from appendicular metastases experience a shorter life
expectancy than those with axial disease only [9]. They
included 86 patients treated initially with androgen depri-
vation as monotherapy. Furthermore, Hovsepian et al.
included 102 previously untreated prostate cancer
patients having bone metastases with or without lung
metastases. They found that patients with >25% involve-
ment of the proximal femur had significantly shorter
survival than those with <25% involvement and with no
lung metastases [10]. A difference between our studies
is that we included all prostate cancer patients (1013)
with bone metastases undergoing a bone scintigraphy
at our department without restricting the inclusion cri-
terion to a specific prostate cancer group. Our study
population is tenfold larger than both Rigauds and
colleges and Hovsepians and colleges and have there-
fore a higher power to address the question whether
localisation of bone metastases can predict survival
or not.
Our dataset also has similar differences in 5 year sur-
vival rates between groups of patients as Singh et al.
[18] reported. The overall survival rate was 43% (75% for
Singh). The survival rate for the 287 patients with no
detected metastases was 74% (90% for Singh) while the
670 patients with detected metastases had a significantly
(p < 0.00001) lower survival rate of 30% (58% for Singh).
In addition, the 342 patients with ≤ 5 metastases had a
much improved survival rate of 50% (73% for Singh) com-
pared to 7% (45% for Singh) for the 328 patients with > 5
metastases (p < 0.00001).
Yamashita et al. [19] found that the presence of bone
metastases outside the pelvis and the lumbar spine is pre-
dictive of shorter survival time among the responders
to androgen deprivation therapy. This suggests that the
localisation of bone metastases may be a prognostic indi-
cator if information of therapy response is also added. We
have not considered therapy response in the analysis and
can therefore not compare our results with theirs. Data
on therapy response would be needed to fully clarify the
prognostic capability of regional BSI. On the other hand,
our group has recently reported that the total BSI-change
between the baseline bone scan and the follow-up can pre-
dict prognosis in metastatic castration-resistant prostate
cancer patients who were receiving docetaxel [6]. 57%
of those with a decrease in total BSI-change were alive
after two years compared with only 18% of those with an
increase in total BSI-change (p = 0.03).
Limitations
The distribution of bone metastases in our data set
may differ from histological data because bone scintig-
raphy can miss some tumors [20,21]. The sensitivity can
be increased with the use of SPECT/CT [22], but this
technique is not routinely applied for all patients at our
institution. Therefore, we could not compare planar BSI
value with SPECT/CT BSI value. A meta-analysis also
indicates that PET/CT has higher sensitivity than planar
bone scan for detecting of metastases and the former will
most likely replace bone scans in the future [23-25]. A
problem that remains to be solved is the high cost and
limited availability of PET/CT.
We have not considered the patients clinical T stage
or the Gleason score in the statistical modeling. Nei-
ther have we considered the patient’s treatment response
or their treatment arsenal, i.e. whether the patients are
newly diagnosed or having castration-resistant prostate
cancer. However, the aim of this study was to investigate
whether one can extract and provide the clinicians with
additional important clinical information from the bone
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scans in order to further help them differentiate between
low-risk and high-risk patients. The outcome of this study
is that the localisations of bone metastases does not
add further clinical information beyond that of the total
BSI-value.
Conclusions
Using two different survival analysis models and a rel-
atively large patient population we have found that
regional BSI measurements does not increase the prog-
nostic capability compared to models that are using
the total BSI. A ranking of the twelve skeletal regions
showed that amodel with BSImeasurements fromCostae,
Pelvis, Scapula, L_spine and Th_spine obtained the same
C-index as a model with only the total BSI (age always
included). Furthermore the survival modeling could not
find any complex interactions between the regional mea-
surements beyond that of a simple additive model. The
overall C-index performance for the different models was
around 70%.
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